BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 32888937)

  • 21. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
    Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
    Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pleural mesothelioma classification-update and challenges.
    Dacic S
    Mod Pathol; 2022 Jan; 35(Suppl 1):51-56. PubMed ID: 34465883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pleural mesothelioma classification update.
    Beasley MB; Galateau-Salle F; Dacic S
    Virchows Arch; 2021 Jan; 478(1):59-72. PubMed ID: 33475835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center.
    Marchevsky AM; LeStang N; Hiroshima K; Pelosi G; Attanoos R; Churg A; Chirieac L; Dacic S; Husain A; Khoor A; Klebe S; Lantuejoul S; Roggli V; Vignaud JM; Weynard B; Sauter J; Henderson D; Nabeshima K; Galateau-Salle F
    Hum Pathol; 2017 Sep; 67():160-168. PubMed ID: 28782639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.
    Galateau Salle F; Le Stang N; Nicholson AG; Pissaloux D; Churg A; Klebe S; Roggli VL; Tazelaar HD; Vignaud JM; Attanoos R; Beasley MB; Begueret H; Capron F; Chirieac L; Copin MC; Dacic S; Danel C; Foulet-Roge A; Gibbs A; Giusiano-Courcambeck S; Hiroshima K; Hofman V; Husain AN; Kerr K; Marchevsky A; Nabeshima K; Picquenot JM; Rouquette I; Sagan C; Sauter JL; Thivolet F; Travis WD; Tsao MS; Weynand B; Damiola F; Scherpereel A; Pairon JC; Lantuejoul S; Rusch V; Girard N
    J Thorac Oncol; 2018 Aug; 13(8):1189-1203. PubMed ID: 29723687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Expression of V-set immunoregulatory receptor in malignant mesothelioma.
    Chung YS; Kim M; Cha YJ; Kim KA; Shim HS
    Mod Pathol; 2020 Feb; 33(2):263-270. PubMed ID: 31363159
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma.
    Shinozaki-Ushiku A; Ushiku T; Morita S; Anraku M; Nakajima J; Fukayama M
    Histopathology; 2017 Apr; 70(5):722-733. PubMed ID: 27859460
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of BAP1 loss and p16 (CDKN2A) deletion analysis to the definitive diagnosis of mesothelioma in effusion cytology.
    Aydogdu G; Özekinci S
    Eur Rev Med Pharmacol Sci; 2023 Oct; 27(20):10001-10007. PubMed ID: 37916370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BRCA1-Associated Protein 1 (BAP1) Immunohistochemical Expression as a Diagnostic Tool in Malignant Pleural Mesothelioma Classification: A Large Retrospective Study.
    Righi L; Duregon E; Vatrano S; Izzo S; Giorcelli J; Rondón-Lagos M; Ascoli V; Ruffini E; Ventura L; Volante M; Papotti M; Scagliotti GV
    J Thorac Oncol; 2016 Nov; 11(11):2006-2017. PubMed ID: 27422796
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspects of histopathologic subtype as a prognostic factor in 85 pleural mesotheliomas.
    Johansson L; Lindén CJ
    Chest; 1996 Jan; 109(1):109-14. PubMed ID: 8549169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA.
    Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
    J Clin Pathol; 2013 Oct; 66(10):854-61. PubMed ID: 23833051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Utility of BAP1 Immunohistochemistry and p16 (CDKN2A) FISH in the Diagnosis of Malignant Mesothelioma in Effusion Cytology Specimens.
    Hwang HC; Sheffield BS; Rodriguez S; Thompson K; Tse CH; Gown AM; Churg A
    Am J Surg Pathol; 2016 Jan; 40(1):120-6. PubMed ID: 26448191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune biomarkers PD-1/PD-L1 and TLR3 in malignant pleural mesotheliomas.
    Combaz-Lair C; Galateau-Sallé F; McLeer-Florin A; Le Stang N; David-Boudet L; Duruisseaux M; Ferretti GR; Brambilla E; Lebecque S; Lantuejoul S
    Hum Pathol; 2016 Jun; 52():9-18. PubMed ID: 26980049
    [TBL] [Abstract][Full Text] [Related]  

  • 34. B7-H1 expression in malignant pleural mesothelioma is associated with sarcomatoid histology and poor prognosis.
    Mansfield AS; Roden AC; Peikert T; Sheinin YM; Harrington SM; Krco CJ; Dong H; Kwon ED
    J Thorac Oncol; 2014 Jul; 9(7):1036-1040. PubMed ID: 24926549
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of carbonic anhydrase IX (CAIX) in malignant mesothelioma. An immunohistochemical and immunocytochemical study.
    Capkova L; Koubkova L; Kodet R
    Neoplasma; 2014; 61(2):161-9. PubMed ID: 24471939
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sarcomatoid Mesothelioma: A Clinicopathological and Immunohistochemical Study of 64 Cases.
    Oramas DM; Zaleski M; Moran CA
    Int J Surg Pathol; 2021 Dec; 29(8):820-825. PubMed ID: 33939493
    [TBL] [Abstract][Full Text] [Related]  

  • 37. c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
    Ren HZ; Cheung S; Churg A
    Hum Pathol; 2020 Nov; 105():31-36. PubMed ID: 32916162
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myxoid variant epithelioid pleural mesothelioma defines a favourable prognosis group: an analysis of 191 patients with pleural malignant mesothelioma.
    Alchami FS; Attanoos RL; Bamber AR
    J Clin Pathol; 2017 Feb; 70(2):179-182. PubMed ID: 27798081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The diagnostic role of BAP1 in serous effusions.
    Davidson B; Tötsch M; Wohlschlaeger J; Hager T; Pinamonti M
    Hum Pathol; 2018 Sep; 79():122-126. PubMed ID: 29802871
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MDM2 and HIF1alpha expression levels in different histologic subtypes of malignant pleural mesothelioma: correlation with pathological and clinical data.
    Pasello G; Urso L; Mencoboni M; Grosso F; Ceresoli GL; Lunardi F; Vuljan SE; Bertorelle R; Sacchetto V; Ciminale V; Rea F; Favaretto A; Conte P; Calabrese F
    Oncotarget; 2015 Dec; 6(39):42053-66. PubMed ID: 26544728
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.